JP2022512689A5 - - Google Patents
Info
- Publication number
- JP2022512689A5 JP2022512689A5 JP2021520223A JP2021520223A JP2022512689A5 JP 2022512689 A5 JP2022512689 A5 JP 2022512689A5 JP 2021520223 A JP2021520223 A JP 2021520223A JP 2021520223 A JP2021520223 A JP 2021520223A JP 2022512689 A5 JP2022512689 A5 JP 2022512689A5
- Authority
- JP
- Japan
- Prior art keywords
- gene therapy
- therapy vector
- vector according
- protein
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744069P | 2018-10-10 | 2018-10-10 | |
| US62/744,069 | 2018-10-10 | ||
| PCT/US2019/055679 WO2020077114A2 (en) | 2018-10-10 | 2019-10-10 | Disulfide bond stabilized polypeptide compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512689A JP2022512689A (ja) | 2022-02-07 |
| JP2022512689A5 true JP2022512689A5 (cg-RX-API-DMAC7.html) | 2022-09-21 |
| JP7577650B2 JP7577650B2 (ja) | 2024-11-05 |
Family
ID=68425288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520223A Active JP7577650B2 (ja) | 2018-10-10 | 2019-10-10 | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
Country Status (17)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102712926B1 (ko) | 2016-10-20 | 2024-10-07 | 상가모 테라퓨틱스, 인코포레이티드 | 파브리병의 치료를 위한 방법 및 조성물 |
| JP7577650B2 (ja) | 2018-10-10 | 2024-11-05 | アミカス セラピューティックス インコーポレイテッド | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
| CN113423419A (zh) | 2019-01-04 | 2021-09-21 | 桑格摩生物治疗股份有限公司 | 用于治疗法布里病的方法和组合物 |
| CN113795575A (zh) | 2019-02-04 | 2021-12-14 | 自由行疗法有限公司 | 多核苷酸 |
| AU2021356684A1 (en) * | 2020-10-09 | 2023-05-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| AR124981A1 (es) * | 2021-02-26 | 2023-05-24 | Takeda Pharmaceuticals Co | Composición y métodos para el tratamiento de la enfermedad de fabry |
| AU2022388800A1 (en) * | 2021-11-12 | 2024-06-27 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of mucopolysaccharidosis iiia |
| US20250034533A1 (en) * | 2021-11-12 | 2025-01-30 | Amicus Therapeutics, Inc. | Compositions And Methods For Treating Mucopolysaccharidosis IIIA |
| US20240408157A1 (en) * | 2021-12-02 | 2024-12-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| AU2024241509A1 (en) * | 2023-03-20 | 2025-09-25 | Spark Therapeutics, Inc. | Ppt1 gene therapy |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
| WO2025264978A2 (en) | 2024-06-20 | 2025-12-26 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a proteins and gene therapy |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000031113A1 (en) | 1998-11-24 | 2000-06-02 | Bristol-Myers Squibb Company | INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| EP1118334A1 (en) | 2000-01-11 | 2001-07-25 | Aventis Behring Gesellschaft mit beschränkter Haftung | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003032913A2 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| PT1587923E (pt) | 2003-01-22 | 2011-12-07 | Univ Duke | Construções melhoradas para a expressão de polipéptidos lisossomais |
| JP4979067B2 (ja) | 2003-05-01 | 2012-07-18 | ジェンザイム・コーポレーション | 神経代謝性疾患についての遺伝子治療 |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| EP1689766B1 (en) | 2003-11-06 | 2012-04-25 | Danisco US Inc. | Expression in filamentous fungi of protease inhibitors and variants thereof |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| ATE474917T1 (de) | 2006-04-11 | 2010-08-15 | Csl Behring Gmbh | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide |
| AU2007322123A1 (en) | 2006-11-13 | 2008-05-29 | Biomarin Pharmaceutical Inc. | Methods for treating Pompe disease |
| WO2009137721A2 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| PL3912643T3 (pl) | 2009-02-13 | 2023-01-23 | Immunomedics Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
| HRP20181315T1 (hr) | 2010-11-22 | 2018-10-19 | Amicus Therapeutics, Inc. | Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| EP2687597B1 (en) | 2011-03-16 | 2018-12-26 | Amano Enzyme Inc. | Modified alpha-glucosidase and applications of same |
| LT2714752T (lt) | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| WO2014022515A1 (en) * | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| ES2679374T3 (es) | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| EP2976092B1 (en) | 2013-03-15 | 2020-04-22 | Amicus Therapeutics, Inc. | Chemical crosslinkers |
| WO2015060722A1 (en) | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| US20170051267A1 (en) | 2015-08-20 | 2017-02-23 | Research Foundation Of The City University Of New York | Novel alpha-galactosidase a derivatives |
| TW202344691A (zh) | 2018-04-30 | 2023-11-16 | 美商阿米庫斯醫療股份有限公司 | 基因治療構築體及使用方法 |
| JP7577650B2 (ja) | 2018-10-10 | 2024-11-05 | アミカス セラピューティックス インコーポレイテッド | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
-
2019
- 2019-10-10 JP JP2021520223A patent/JP7577650B2/ja active Active
- 2019-10-10 BR BR112021006829-5A patent/BR112021006829A2/pt not_active IP Right Cessation
- 2019-10-10 KR KR1020217013640A patent/KR102743734B1/ko active Active
- 2019-10-10 SG SG11202103640VA patent/SG11202103640VA/en unknown
- 2019-10-10 EA EA202190999A patent/EA202190999A1/ru unknown
- 2019-10-10 AR ARP190102882A patent/AR116624A1/es not_active Application Discontinuation
- 2019-10-10 EP EP19797444.7A patent/EP3863663A2/en active Pending
- 2019-10-10 MX MX2021004188A patent/MX2021004188A/es unknown
- 2019-10-10 US US16/598,960 patent/US11097015B2/en active Active
- 2019-10-10 CN CN201980078576.0A patent/CN113631182B/zh active Active
- 2019-10-10 AU AU2019359385A patent/AU2019359385B2/en active Active
- 2019-10-10 WO PCT/US2019/055679 patent/WO2020077114A2/en not_active Ceased
- 2019-10-10 CA CA3115944A patent/CA3115944A1/en active Pending
- 2019-10-14 TW TW108136956A patent/TW202027781A/zh unknown
-
2021
- 2021-04-09 CL CL2021000883A patent/CL2021000883A1/es unknown
- 2021-04-09 PH PH12021550789A patent/PH12021550789A1/en unknown
- 2021-04-09 IL IL282205A patent/IL282205A/en unknown
- 2021-06-30 US US17/363,333 patent/US12064485B2/en active Active
-
2024
- 2024-08-19 US US18/808,596 patent/US20250242057A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI920044B (zh) | 用於治療龐貝症及溶酶體病症之包含肝特異性啟動子之治療性腺相關病毒 | |
| ES2371913T3 (es) | Constructos mejorados para expresar polipéptidos lisosomales. | |
| TWI808169B (zh) | 基因治療構築體及使用方法 | |
| JP2021521851A5 (cg-RX-API-DMAC7.html) | ||
| CN113631182B (zh) | 二硫键稳定的多肽组合物和使用方法 | |
| CA3133453A1 (en) | Recombinant adeno-associated virus vectors | |
| CA3120105A1 (en) | Therapeutic adeno-associated virus for treating pompe disease | |
| US20220133906A1 (en) | Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal teargeting sequence | |
| JP2022552254A (ja) | バリアントigf2構築体 | |
| CN119876200A (zh) | 密码子优化的补体因子i | |
| AU2021273273A1 (en) | Compositions useful for treatment of pompe disease | |
| JP2024519819A (ja) | 眼疾患および障害を処置するための方法および組成物 | |
| US20240271115A1 (en) | Methods and compositions for depleting antibodies | |
| US20240318157A1 (en) | Neurotensin Variants And Tagged Proteins Comprising Neurotensin Or Sortilin Propeptide | |
| KR20250110842A (ko) | 대사질환을 위한 유전자 요법 구성체 | |
| JP2025515030A5 (cg-RX-API-DMAC7.html) | ||
| US20220347315A1 (en) | Methods and compositions for increasing transduction efficiency with cell membrane fusion proteins | |
| EP4516913A1 (en) | Aav vector optimized for intrathecal administration into which hepatocyte growth factor gene is introduced | |
| KR102814185B1 (ko) | 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물 | |
| JP2024546578A5 (cg-RX-API-DMAC7.html) | ||
| HK40053744A (zh) | 二硫键稳定的多肽组合物和使用方法 | |
| HK40039189A (en) | Gene therapy constructs and methods of use | |
| KR20250080845A (ko) | 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물 | |
| RU2021101685A (ru) | Оптимизированные гены cln5 и кассеты для их экспрессии, и их применение | |
| HK40053744B (en) | Disulfide bond stabilized polypeptide compositions and methods of use |